Roger Bullock

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

Clive Holmes, Delphine Boche, David Wilkinson et al. · The Lancet · 2008 · 1.4K citations

Life Sciences, Immunology, Neurology +16

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Lawrence S. Honig, Bruno Vellas, Merçé Boada et al. · New England Journal of Medicine · 2018 · 1K citations · Full text

Medicine, Neurology, Pharmacology +17

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

Timo Erkinjuntti, Alexander Kurz, Serge Gauthier et al. · The Lancet · 2002 · 761 citations

Medicine, Neurology, Pharmacotherapy +15

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Juha O. Rinne, David J. Brooks, Martin N. Rossor et al. · The Lancet Neurology · 2010 · 695 citations

Life Sciences, Neurology, Neuroscience +17

Donepezil for the Treatment of Agitation in Alzheimer's Disease

Robert Howard, Edmund Juszczak, Clive Ballard et al. · New England Journal of Medicine · 2007 · 325 citations · Full text

Medicine, Pharmacotherapy, Psychiatry +17